Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141854 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
NCT02141854 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 882 participants.
The verdict
NCT02141854, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.
Interventions
- DRUG Placebo MDPI
- DRUG Fp MDPI
- DRUG FS MDPI
- DRUG Albuterol/salmeterol HFA MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141854
The ClinicalTrials.gov registry entry for NCT02141854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo MDPI is the first listed.
NCT02141854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141854 about?
NCT02141854 is a clinical study titled "Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma". The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.
What is the current status of trial NCT02141854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2014-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02141854?
The interventions under investigation include: Placebo MDPI (DRUG), Fp MDPI (DRUG), FS MDPI (DRUG), Albuterol/salmeterol HFA MDI (DRUG).
Who is sponsoring clinical trial NCT02141854?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.